$CARM
Carisma Therapeutics Inc

2023 Q2 Form 10-Q Financial Statement

#000110465923058778 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $3.600M $3.243M $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.010M $9.570M $7.080M
YoY Change -61.45% 6.63% -17.64%
% of Gross Profit
Research & Development $18.52M $16.64M $960.0K
YoY Change -38.16% 249.6% -86.36%
% of Gross Profit
Depreciation & Amortization $710.0K $710.0K $0.00
YoY Change 23566.67% 7000.0% -100.0%
% of Gross Profit
Operating Expenses $24.53M $26.22M $8.040M
YoY Change -31.87% 3039.52% -27.14%
Operating Profit -$20.97M -$22.97M
YoY Change -41.76% 2651.14%
Interest Expense $1.177M -$1.477M $1.850M
YoY Change -252.66% 146.58%
% of Operating Profit
Other Income/Expense, Net -$570.0K
YoY Change 3700.0%
Pretax Income -$19.79M -$24.53M -$7.570M
YoY Change -44.77% 2939.65% -184.64%
Income Tax $88.00K $109.0K $0.00
% Of Pretax Income
Net Earnings -$19.88M -$24.64M -$7.570M
YoY Change -37.81% 2953.53% -184.64%
Net Earnings / Revenue -552.11% -759.85%
Basic Earnings Per Share -$0.49 -$1.93
Diluted Earnings Per Share -$0.49 -$1.93 -$0.75
COMMON SHARES
Basic Shares Outstanding 40.25M 203.5M shares 202.8M shares
Diluted Shares Outstanding 40.26M shares 12.78M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $117.1M $139.0M $166.9M
YoY Change -17.27% -18.13% 2.62%
Cash & Equivalents $76.35M $62.78M $112.6M
Short-Term Investments $40.70M $76.20M $54.40M
Other Short-Term Assets $5.100M $5.500M $21.40M
YoY Change 573.71% -37.46% 15.83%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $800.0K
Total Short-Term Assets $122.2M $144.5M $189.1M
YoY Change -21.88% -20.0% -8.01%
LONG-TERM ASSETS
Property, Plant & Equipment $7.590M $8.107M $0.00
YoY Change 25200.0% 24466.67% -100.0%
Goodwill $0.00
YoY Change -100.0%
Intangibles $0.00
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets $200.0K $0.00 $0.00
YoY Change 376.19% -100.0% -100.0%
Total Long-Term Assets $10.81M $11.63M $30.00K
YoY Change -45.23% -74.27% -99.91%
TOTAL ASSETS
Total Short-Term Assets $122.2M $144.5M $189.1M
Total Long-Term Assets $10.81M $11.63M $30.00K
Total Assets $133.0M $156.1M $189.2M
YoY Change -24.49% -30.87% -21.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.487M $4.614M $1.233M
YoY Change 49.19% 592.79% -56.78%
Accrued Expenses $9.614M $10.19M $29.64M
YoY Change -67.79% 39.97% 259.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M $1.200M
YoY Change
Total Short-Term Liabilities $17.97M $21.48M $30.98M
YoY Change -43.84% 153.45% 167.84%
LONG-TERM LIABILITIES
Long-Term Debt $600.0K $700.0K $0.00
YoY Change
Other Long-Term Liabilities $1.809M $1.897M $1.041M
YoY Change 0.5% -95.33%
Total Long-Term Liabilities $1.809M $1.897M $0.00
YoY Change 0.5% -95.74% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.97M $21.48M $30.98M
Total Long-Term Liabilities $1.809M $1.897M $0.00
Total Liabilities $66.31M $70.06M $30.98M
YoY Change 96.15% 32.09% -55.12%
SHAREHOLDERS EQUITY
Retained Earnings -$202.7M -$182.9M -$336.1M
YoY Change -41.92% -42.31% 6.27%
Common Stock $40.00K $40.00K $202.0K
YoY Change -79.9% -79.9% 1.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.71M $86.07M $158.2M
YoY Change
Total Liabilities & Shareholders Equity $133.0M $156.1M $189.2M
YoY Change -24.49% -30.87% -21.42%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$19.88M -$24.64M -$7.570M
YoY Change -37.81% 2953.53% -184.64%
Depreciation, Depletion And Amortization $710.0K $710.0K $0.00
YoY Change 23566.67% 7000.0% -100.0%
Cash From Operating Activities -$18.55M -$25.53M $2.690M
YoY Change 115.82% -456.92% -121.35%
INVESTING ACTIVITIES
Capital Expenditures $240.0K $135.0K
YoY Change -86.59%
Acquisitions
YoY Change
Other Investing Activities $36.00M -$3.460M $59.76M
YoY Change -140.41%
Cash From Investing Activities $35.76M -$3.595M $59.76M
YoY Change -140.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.630M 67.74M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -18.55M -25.53M 2.690M
Cash From Investing Activities 35.76M -3.595M 59.76M
Cash From Financing Activities -3.630M 67.74M 0.000
Net Change In Cash 13.58M 38.61M 62.45M
YoY Change -113.9% 439.74% -595.63%
FREE CASH FLOW
Cash From Operating Activities -$18.55M -$25.53M $2.690M
Capital Expenditures $240.0K $135.0K
Free Cash Flow -$18.79M -$25.67M
YoY Change 118.62% -517.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.49
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12783523
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2059986
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40254666
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2217737
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36296
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Carisma Therapeutics Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2025616
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3675 Market Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Philadelphia
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19104
CY2023Q1 dei City Area Code
CityAreaCode
267
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
491-6422
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
CARM
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40254666
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62777000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24194000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
76190000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
27802000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5535000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2596000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
144502000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
54592000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8107000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8628000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3493000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4822000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
30000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
4111000
CY2023Q1 us-gaap Assets
Assets
156132000
CY2022Q4 us-gaap Assets
Assets
72153000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4614000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1728000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10187000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10361000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2136000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2459000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2597000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3437000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1188000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1162000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
755000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
523000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
21477000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19670000
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
45000000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
45000000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
33717000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5739000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
948000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
976000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
740000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
872000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1897000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1041000
CY2023Q1 us-gaap Liabilities
Liabilities
70062000
CY2022Q4 us-gaap Liabilities
Liabilities
107015000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
107808000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40254666
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2217737
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
40000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
268759000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1197000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
136000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-41000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182865000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158223000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
86070000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-157065000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
14395000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86070000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-142670000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
156132000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72153000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3243000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
822000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16641000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8767000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9574000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2211000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
26215000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
10978000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22972000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10156000
CY2023Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-84000
CY2022Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-557000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1477000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-599000
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-24533000
CY2022Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-11312000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
109000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24642000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11312000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.93
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.49
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.49
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12783523
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12783523
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2059986
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2059986
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24642000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11312000
CY2023Q1 carm Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax
OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax
177000
CY2022Q1 carm Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax
OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax
-158000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24465000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11470000
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
8700885
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
107808000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-142670000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
265000
CY2023Q1 carm Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax
OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax
177000
CY2023Q1 carm Stock Issued During Period Values Preclosure Financing Transaction
StockIssuedDuringPeriodValuesPreclosureFinancingTransaction
30640000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
42447000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
72044000
CY2023Q1 carm Reclassifications Of Temporary To Permanent Equity Shares
ReclassificationsOfTemporaryToPermanentEquityShares
-8700885
CY2023Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
-107808000
CY2023Q1 carm Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests Upon Merger
StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
107809000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-24642000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86070000
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
8700885
CY2021Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
107808000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-81784000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
89000
CY2022Q1 carm Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax
OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax
-158000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-11312000
CY2022Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
8700885
CY2022Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
107808000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-93165000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-24642000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-11312000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
705000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
218000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
265000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
89000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1329000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
381000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1283000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
623000
CY2023Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-84000
CY2022Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-557000
CY2023Q1 carm Accretion On Marketable Securities
AccretionOnMarketableSecurities
163000
CY2023Q1 carm Noncash Interest Expense
NoncashInterestExpense
41000
CY2022Q1 carm Noncash Interest Expense
NoncashInterestExpense
59000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1623000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1607000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2823000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2612000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4445000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2259000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-323000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
45619000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-868000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-376000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25534000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34604000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34460000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
63244000
CY2023Q1 carm Payments For Proceeds From Marketable Securities
PaymentsForProceedsFromMarketableSecurities
-31000000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
135000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1007000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3595000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64251000
CY2023Q1 carm Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities
CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities
37903000
CY2023Q1 carm Payment Of Finance Costs Reverse Recapitalization Financing Activities
PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities
1742000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30640000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
106000
CY2023Q1 carm Proceeds From Failed Sale Leaseback Transaction
ProceedsFromFailedSaleLeasebackTransaction
1092000
CY2023Q1 carm Payment Of Finance Liability Failed Sale Leaseback Transaction
PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
45000
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
35000000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67742000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
38613000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5353000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24194000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28551000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62807000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33904000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
45000
CY2023Q1 carm Noncash Or Part Noncash Acquisition Equity Assumed
NoncashOrPartNoncashAcquisitionEquityAssumed
122204000
CY2023Q1 us-gaap Notes Reduction
NotesReduction
42447000
CY2023Q1 carm Noncash Or Part Noncash Reverse Recapitalization Costs In Accrued Expenses
NoncashOrPartNoncashReverseRecapitalizationCostsInAccruedExpenses
4071000
CY2023Q1 carm Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities
NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities
177000
CY2022Q1 carm Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities
NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities
-158000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3072000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Debt Assumed1
NoncashOrPartNoncashAcquisitionDebtAssumed1
3820000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
49000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
103000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182900000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
139000000.0
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Significant areas that require management’s estimates include the fair value of the Company’s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</p>
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4184047
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16747587
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
37873000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
44588000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
1316000
CY2023Q1 carm Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash
Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash
30000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
3499000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
80308000
CY2023Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
8264000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
72044000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1433000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
465000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
297000
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
45000
CY2023Q1 carm Finance Lease Cost
FinanceLeaseCost
342000
CY2023Q1 us-gaap Lease Cost
LeaseCost
1775000
CY2022Q1 us-gaap Lease Cost
LeaseCost
465000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.090
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1448000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
461000
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
45000
CY2023Q1 carm Financing Cash Used In Finance Leases
FinancingCashUsedInFinanceLeases
106000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
144352
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.64
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
82427
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.46
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
38
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.46
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4184047
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2713000
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1150000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
213000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
600000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
219000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
338000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
226000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
233000
CY2023Q1 carm Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
423000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4027000
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2088000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
482000
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
160000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3545000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1928000
CY2023Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
200000
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3730608
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.21
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30600000
CY2023Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
5059338
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
35000000.0
CY2023Q1 carm Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests
StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests
18872711
CY2023Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
10374272
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3356937
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.01
CY2023Q1 carm Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross
765223
CY2023Q1 carm Share Based Compensation Arrangements By Share Based Payment Award Options Assumed In Merger Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice
27.94
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.11
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6798000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3015084
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.58
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M6D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5057000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4184047
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.11
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
6798000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.64
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.75
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
265000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
89000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2023Q1 carm Tax Revenue Related To Collaboration And License Agreement With Related Party
TaxRevenueRelatedToCollaborationAndLicenseAgreementWithRelatedParty
45000000.0
CY2023Q1 carm Revenue Remaining Performance Obligation Research And Development Amount
RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount
61376000
CY2023Q1 carm Revenue Remaining Performance Obligation Option Rights Amount
RevenueRemainingPerformanceObligationOptionRightsAmount
45000000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
106376000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
47459000
CY2023Q1 carm Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
2920000
CY2022Q1 carm Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
46441000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-3243000
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-822000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
47136000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45619000

Files In Submission

Name View Source Status
0001104659-23-058778-index-headers.html Edgar Link pending
0001104659-23-058778-index.html Edgar Link pending
0001104659-23-058778.txt Edgar Link pending
0001104659-23-058778-xbrl.zip Edgar Link pending
carm-20230331.xsd Edgar Link pending
carm-20230331x10q.htm Edgar Link pending
carm-20230331xex10d18.htm Edgar Link pending
carm-20230331xex31d1.htm Edgar Link pending
carm-20230331xex31d2.htm Edgar Link pending
carm-20230331xex32d1.htm Edgar Link pending
carm-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
carm-20230331_cal.xml Edgar Link unprocessable
carm-20230331_def.xml Edgar Link unprocessable
carm-20230331_lab.xml Edgar Link unprocessable
carm-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
carm-20230331x10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending